首页> 外文期刊>Molecular cancer therapeutics >Multiple Antigenic Peptides Based on H-2Kb-Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo.
【24h】

Multiple Antigenic Peptides Based on H-2Kb-Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo.

机译:基于H-2Kb限制性CTL表位的鼠类乙酰肝素酶的多个抗原肽在体内诱导有效的抗肿瘤免疫反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Accumulating research suggests that heparanase may be a universal tumor-associated antigen (TAA). Several heparanase T-cell epitopes from humans and mice have already been identified. However, because of low immunogenicity, polypeptide vaccines usually have difficulty inducing effective antitumor immune responses in vivo. In this study, to increase the immunogenicity of polypeptide vaccines, we designed and synthesized two four-branch multiple antigenic peptides (MAP) on the basis of mouse heparanase (mHpa) T-cell epitopes (mHpa398 and mHpa519). The dendritic cells (DC) from mice bone marrow loaded with above MAP vaccines from heparanase were used to evaluate immune response against various tumor cell lines, compared with immune response to their corresponding linear peptides, ex vivo and in vivo. We further assessed IFN-γ release both in CD4(+) T-cell-depleted and nondepleted mice. The results showed that effectors generated from DCs, loaded with MAP-vaccinated mice splenocytes, induced a stronger immune response against target cells expressing both heparanase and H-2K(b) than did effectors generated from mice vaccinated with their corresponding linear peptides. Heparanase-specific CD8(+) T-cell responses induced by MAP and linear peptide vaccination required synergy of CD4(+) T cells. In addition, heparanse-derived MAP vaccines significantly inhibited the growth of B16 murine melanoma in C57BL/6 mice, while also increasing the survival rate of tumor-bearing mice. Our data suggest that MAP vaccines based on T-cell epitopes from heparanase are efficient immunogens for tumor immunotherapy. Mol Cancer Ther; 11(5); 1183-92. ?2012 AACR.
机译:越来越多的研究表明,乙酰肝素酶可能是一种通用的肿瘤相关抗原(TAA)。已经鉴定了来自人和小鼠的几种乙酰肝素酶T细胞表位。然而,由于免疫原性低,多肽疫苗通常难以在体内诱导有效的抗肿瘤免疫应答。在这项研究中,为了提高多肽疫苗的免疫原性,我们在小鼠乙酰肝素酶(mHpa)T细胞表位(mHpa398和mHpa519)的基础上设计并合成了两个四支多抗原肽(MAP)。与来自其的相应线性肽的免疫反应相比,来自小鼠骨髓的树突状细胞(DC)负载有以上乙酰肝素酶的MAP疫苗,用于评估针对各种肿瘤细胞系的免疫反应,而离体和体内免疫反应均与之相对应。我们进一步评估了CD4(+)T细胞贫化和非贫血小鼠的IFN-γ释放。结果表明,与接种了相应线性肽的小鼠产生的效应物相比,负载MAP疫苗的小鼠脾细胞的DC产生的效应物对表达肝素酶和H-2K(b)的靶细胞诱导了更强的免疫反应。 MAP和线性肽疫苗接种诱导的肝素酶特异性CD8(+)T细胞应答需要CD4(+)T细胞协同作用。另外,肝素衍生的MAP疫苗显着抑制了C57BL / 6小鼠中B16鼠黑色素瘤的生长,同时还提高了荷瘤小鼠的存活率。我们的数据表明,基于乙酰肝素酶T细胞表位的MAP疫苗是用于肿瘤免疫疗法的有效免疫原。分子癌疗法; 11(5); 1183-92。 2012年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号